ArticleiScience2026
OSBPL2 deficiency alleviates diet-induced MASLD by reducing ACSL4-mediated ferroptosis.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolic dysfunction-associated steatotic liver disease: pathogenic mechanisms and exercise-induced molecular adaptations.Lipids in health and disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oxysterol-binding protein-like 2 (OSBPL2) is a lipid transfer protein that modulates intracellular lipid homeostasis; however, its regulatory role in coordinating iron and fatty acid homeostasis remains largely elusive. A recent study has reported a strong positive correlation between iron overload and the progression of metabolic dysfunction-associated steatotic liver disease (MASLD). Herein, we found that OSBPL2 binds to HSP90β, and OSBPL2 deficiency inhibits ACSL4 expression while altering hepatic fatty acid distribution by impairing lipolysis. Depletion of OSBPL2 conferred resistance to ferroptosis via the ACSL4-mediated ferroptosis pathway and further attenuated diet-induced liver fibrosis in mice. Our findings provide important insights into the function of OSBPL2 in ferroptosis and suggest that OSBPL2 may serve as a potential therapeutic target for MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.